197 related articles for article (PubMed ID: 24737320)
1. Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.
Ding K; Banerjee A; Tan S; Zhao J; Zhuang Q; Li R; Qian P; Liu S; Wu ZS; Lobie PE; Zhu T
J Biol Chem; 2014 Jun; 289(23):16057-71. PubMed ID: 24737320
[TBL] [Abstract][Full Text] [Related]
2. Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.
Banerjee A; Qian P; Wu ZS; Ren X; Steiner M; Bougen NM; Liu S; Liu DX; Zhu T; Lobie PE
J Biol Chem; 2012 Dec; 287(51):42502-15. PubMed ID: 23095743
[TBL] [Abstract][Full Text] [Related]
3. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
[TBL] [Abstract][Full Text] [Related]
4. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
5. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
[TBL] [Abstract][Full Text] [Related]
6. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.
Banerjee A; Wu ZS; Qian P; Kang J; Pandey V; Liu DX; Zhu T; Lobie PE
Breast Cancer Res; 2011; 13(6):R112. PubMed ID: 22060274
[TBL] [Abstract][Full Text] [Related]
7. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.
Korkaya H; Paulson A; Iovino F; Wicha MS
Oncogene; 2008 Oct; 27(47):6120-30. PubMed ID: 18591932
[TBL] [Abstract][Full Text] [Related]
8. ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.
Banerjee A; Wu ZS; Qian PX; Kang J; Liu DX; Zhu T; Lobie PE
PLoS One; 2012; 7(11):e50098. PubMed ID: 23185544
[TBL] [Abstract][Full Text] [Related]
9. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
10. ARTEMIN Promotes Oncogenicity and Resistance to 5-Fluorouracil in Colorectal Carcinoma by p44/42 MAPK Dependent Expression of CDH2.
Zhuang QS; Sun XB; Chong QY; Banerjee A; Zhang M; Wu ZS; Zhu T; Pandey V; Lobie PE
Front Oncol; 2021; 11():712348. PubMed ID: 34422665
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.
Oak PS; Kopp F; Thakur C; Ellwart JW; Rapp UR; Ullrich A; Wagner E; Knyazev P; Roidl A
Int J Cancer; 2012 Dec; 131(12):2808-19. PubMed ID: 22511343
[TBL] [Abstract][Full Text] [Related]
12. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).
Diessner J; Bruttel V; Stein RG; Horn E; Häusler SF; Dietl J; Hönig A; Wischhusen J
Cell Death Dis; 2014 Mar; 5(3):e1149. PubMed ID: 24675467
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
Chakrabarty A; Bhola NE; Sutton C; Ghosh R; Kuba MG; Dave B; Chang JC; Arteaga CL
Cancer Res; 2013 Feb; 73(3):1190-200. PubMed ID: 23204226
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
15. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the expression of GFRα1, GFRα3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma.
Wu ZS; Pandey V; Wu WY; Ye S; Zhu T; Lobie PE
BMC Cancer; 2013 Jan; 13():34. PubMed ID: 23351331
[TBL] [Abstract][Full Text] [Related]
17. Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2.
Tang JZ; Kong XJ; Kang J; Fielder GC; Steiner M; Perry JK; Wu ZS; Yin Z; Zhu T; Liu DX; Lobie PE
Mol Cancer Ther; 2010 Jun; 9(6):1697-708. PubMed ID: 20530713
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
20. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Ritter CA; Perez-Torres M; Rinehart C; Guix M; Dugger T; Engelman JA; Arteaga CL
Clin Cancer Res; 2007 Aug; 13(16):4909-19. PubMed ID: 17699871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
